AAAAAA

   
Results: 1-17 |
Results: 17
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression
Authors: Havlir, DV Gilbert, PB Bennett, K Collier, AC Hirsch, MS Tebas, P Adams, EM Wheat, LJ Goodwin, D Schnittman, S Holohan, MK Richman, DD
Citation: Dv. Havlir et al., Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression, AIDS, 15(11), 2001, pp. 1379-1388
Prevalence and predictive value of intermittent viremia with combination HIV therapy
Authors: Havlir, DV Bassett, R Levitan, D Gilbert, P Tebas, P Collier, AC Hirsch, MS Ignacio, C Condra, J Gunthard, HF Richman, DD Wong, JK
Citation: Dv. Havlir et al., Prevalence and predictive value of intermittent viremia with combination HIV therapy, J AM MED A, 286(2), 2001, pp. 171-179
Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease
Authors: Havlir, DV Torriani, FJ Schrier, RD Huang, JY Lederman, MM Chervenak, KA Boom, WH
Citation: Dv. Havlir et al., Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease, J CLIN MICR, 39(1), 2001, pp. 298-303
Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years
Authors: Gunthard, HF Havlir, DV Fiscus, S Zhang, ZQ Eron, J Mellors, J Gulick, R Frost, SDW Brown, AJL Schleif, W Valentine, F Jonas, L Meibohm, A Ignacio, CC Isaacs, R Gamagami, R Emini, E Haase, A Richman, DD Wong, JK
Citation: Hf. Gunthard et al., Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years, J INFEC DIS, 183(9), 2001, pp. 1318-1327
Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy
Authors: O'Brien, TR McDermott, DH Ioannidis, JPA Carrington, M Murphy, PM Havlir, DV Richman, DD
Citation: Tr. O'Brien et al., Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy, AIDS, 14(7), 2000, pp. 821-826
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients
Authors: Zhou, XJ Havlir, DV Richman, DD Acosta, EP Hirsch, M Collier, AC Tebas, P Sommadossi, JP
Citation: Xj. Zhou et al., Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients, AIDS, 14(18), 2000, pp. 2869-2876
Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication
Authors: Ioannidis, JPA Havlir, DV Tebas, P Hirsch, MS Collier, AC Richman, DD
Citation: Jpa. Ioannidis et al., Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication, AIDS, 14(11), 2000, pp. 1481-1488
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
Authors: Havlir, DV Hellmann, NS Petropoulos, CJ Whitcomb, JM Collier, AC Hirsch, MS Tebas, P Sommadossi, JP Richman, DD
Citation: Dv. Havlir et al., Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens, J AM MED A, 283(2), 2000, pp. 229-234
Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects
Authors: Havlir, DV Schrier, RD Torriani, FJ Chervenak, K Hwang, JY Boom, WH
Citation: Dv. Havlir et al., Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects, J INFEC DIS, 182(6), 2000, pp. 1658-1663
In vivo antagonism with zidovudine plus stavudine combination therapy
Authors: Havlir, DV Tierney, C Friedland, GH Pollard, RB Smeaton, L Sommadossi, JP Fox, L Kessler, H Fife, KH Richman, DD
Citation: Dv. Havlir et al., In vivo antagonism with zidovudine plus stavudine combination therapy, J INFEC DIS, 182(1), 2000, pp. 321-325
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
Authors: Appay, V Nixon, DF Donahoe, SM Gillespie, GMA Dong, T King, A Ogg, GS Spiegel, HML Conlon, C Spina, CA Havlir, DV Richman, DD Waters, A Easterbrook, P McMichael, AJ Rowland-Jones, SL
Citation: V. Appay et al., HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function, J EXP MED, 192(1), 2000, pp. 63-75
Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS
Authors: Dube, MP Torriani, FJ See, D Havlir, DV Kemper, CA Leedom, JM Tilles, JG McCutchan, JA Sattler, FR
Citation: Mp. Dube et al., Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS, CLIN INF D, 28(1), 1999, pp. 136-138
Tuberculosis in patients with human immunodeficiency virus infection
Authors: Havlir, DV Barnes, PF
Citation: Dv. Havlir et Pf. Barnes, Tuberculosis in patients with human immunodeficiency virus infection, N ENG J MED, 340(5), 1999, pp. 367-373
Reversibility of the pathological changes in the follicular dendritic cellnetwork with treatment of HIV-1 infection
Authors: Zhang, ZQ Schuler, T Cavert, W Notermans, DW Gebhard, K Henry, K Havlir, DV Gunthard, HF Wong, JK Little, S Feinberg, MB Polis, MA Schrager, LK Schacker, TW Richman, DD Corey, L Danner, SA Haase, AT
Citation: Zq. Zhang et al., Reversibility of the pathological changes in the follicular dendritic cellnetwork with treatment of HIV-1 infection, P NAS US, 96(9), 1999, pp. 5169-5172
Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
Authors: Gunthard, HF Frost, SDW Leigh-Brown, AJ Ignacio, CC Kee, K Perelson, AS Spina, CA Havlir, DV Hezareh, M Looney, DJ Richman, DD Wong, JK
Citation: Hf. Gunthard et al., Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy, J VIROLOGY, 73(11), 1999, pp. 9404-9412
Viral dynamics of acute HIV-1 infection
Authors: Little, SJ McLean, AR Spina, CA Richman, DD Havlir, DV
Citation: Sj. Little et al., Viral dynamics of acute HIV-1 infection, J EXP MED, 190(6), 1999, pp. 841-850
Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS
Authors: Havlir, DV Dube, MP McCutchan, JA Forthal, DN Kemper, CA Dunne, MW Parenti, DM Kumar, PN White, AC Witt, MD Nightingale, SD Sepkowitz, KA MacGregor, RR Cheeseman, SH
Citation: Dv. Havlir et al., Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS, CLIN INF D, 27(6), 1998, pp. 1369-1375
Risultati: 1-17 |